BEAM THERAPEUTICS IN (BEAM) is drawing unusual attention today. Our newswire has captured 5 stories on BEAM across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
BEAM stock fell 9.54% to $26.83 on September 8, driven by updated clinical data from its Phase 1/2 trial for BEAM-302, a gene-editing therapy for alpha-1 antitrypsin deficiency. The data, presented at the European Respiratory Society Congress 2026, failed to meet expectations, prompting the company to adjust its regulatory strategy. Beam Therapeutics announced it will pursue an accelerated approval pathway and add 50 more patients to its trial.
Beam Therapeutics released updated results for BEAM-302, its one-time gene-editing treatment for AATD, showing AAT protein production under normal physiological control. However, the data did not meet the expectations of investors or analysts, leading to a sharp decline in the stock. The company announced it will seek accelerated approval from the FDA and enroll additional patients to support a future biologics license application. This shift in strategy signals a longer path to commercialization than previously anticipated.
The stock has been volatile in recent weeks, with insiders including CEO John M. Evans and Chief Medical Officer Simon Amy selling shares. The CMO sold on both June 30 and July 27, while the CEO sold on June 29. The most recent insider sale was reported on July 29. Over the past 8 sessions, the stock has declined 11.7% from $30.48 to $26.90.
The stock has a market cap of $3.0B and is currently unprofitable, with a trailing twelve-month EPS of -0.84 and a net margin of -55.4%. Revenue grew by 158.9% in the TTM period. The stock traded within a 52-week range of $17.74 to $38.26. On September 8, it printed two fresh 52-week lows and one fresh 52-week high. Volume was unusually high, though specific figures are not provided. The stock’s beta of 2.23 indicates strong volatility relative to the broader market.
Beam Therapeutics is scheduled to present further updates on BEAM-302 in the coming weeks. Investors will also monitor the company’s progress toward its accelerated approval pathway and any changes in coverage from analysts.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BEAM-301 is a one-time liver-targeted treatment designed to correct a common genetic error that causes glycogen storage disease type Ia, or GSDIa.
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a October 27, 2026 8:00 AM EDTCompany...
In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment Safety Profile of BEAM-301...
BEAM THERAPEUTICS IN (BEAM) is drawing unusual attention today. Our newswire has captured 5 stories on BEAM across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100). The most recent driver: "BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside" (Stocktwits News).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of BEAM coverage reads 66/100 over 5 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on BEAM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BEAM move explainers: 2026-09-09 · 2026-09-08 · 2026-08-26 · 2026-08-25 · 2026-08-20